BRAF is one of the most frequently mutated oncogenes, with an overall frequency of about
50%. Targeting BRAF and its effector mitogen-activated protein kinase kinase 1/2 (MEK1/2) …

Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF
has enabled a “precision medicine” paradigm to diagnose and treat BRAF-driven tumors …

Opinion Statement BRAF mutations are present in up to 8% of human cancers, and
comprise a viable therapeutic target in many patients harboring these mutations. Specific …

Abstract Purpose of Review This report highlights several of the recent therapeutic
advancements in the treatment of BRAF-mutant tumors, discusses the most common …

BRAF is a serine-threonine–specific protein kinase that is mutated in 2% of human cancers.
Oncogenic BRAF is a validated therapeutic target that constitutively activates mitogen …

BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant
number of cancers, including melanoma, thyroid cancer, colorectal cancer and others …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown
promising results in patients with tumors harboring BRAF V600 mutations. However, as has …

Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …

Background Mutations in BRAF were first reported in 2002. Since that time, the molecular
basis for oncogenic signaling has been elucidated in multiple malignancies. The …